Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Symproic® approved by FDA

    by
    • Optum Workers' Comp
    | Mar 28, 2017
    Tag Icon
    Opioids
    The U.S. Food and Drug Administration (FDA) has approved a new oral medication for the treatment of opioid-induced constipation (OIC). Symproic® (naldemedine) is an opioid antagonist indicated to treat OIC in adult patients with chronic non-cancer pain.


  • Summary of Texas HB 2830

    by
    • Optum Workers' Comp
    | Mar 22, 2017
    Tag Icon
    Workers' Compensation, FDA, Formularies
    The Texas Division of Workers’ Compensation (DWC) instituted a closed drug formulary based on Appendix A of the Official Disability Guidelines (ODG) published in September 2011.


  • California DWC releases formal draft of MTUS drug formulary rule

    by
    • Optum Workers' Comp
    | Mar 21, 2017
    Tag Icon
    Formularies
    The California Division of Workers’ Compensation (DWC) has released the long-awaited formal draft of the MTUS Drug Formulary. As drafted, the formulary would initiate for new claims beginning on July 1, 2017. Unlike some other states, California has proposed its own unique list of medications for inclusion.


  • Addressing opioid analgesic use in workers' comp and auto no-fault

    by
    • Optum Workers' Comp
    | Mar 20, 2017
    Tag Icon
    Workers' Compensation, Opioids
    We are pleased to release our latest insight on addresing opioid analgesic use in workers' comp and auto no-fault. Inside you will find statistical trends impacting opioid analgesics today and our perspective on opioid analgesic use.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.